Patent · US Active

Use of inhibitors of scinderin and/or ephrin-A1 for treating tumors

US8058252B2 · kind B2 · utility

4Cited by
1References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 28, 2006
Grant dateNov 15, 2011
Priority date
Expiry dateMar 17, 2027

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/14
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to the use of inhibitors of the expression or the activity of scinderin and/or of ephrin-A1 inhibitors for increasing the susceptibility of tumor cells to CTL killing. Such inhibitors may be for instance interfering RNAs targeting the scinderin gene and/or interfering RNAs targeting the ephrin-A1 gene.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.